

1
--Claim 128. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO: 11, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

2
Claim 129. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO: 48, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

3
Claim 130. The method of claim 128, wherein the antibody further comprises a VH domain having an amino acid sequence of SEQ ID NO: 48.

4
Claim 131. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO: 10, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

5
Claim 132. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO: 19, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim ⁶133. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 20, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim ⁷134. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 39, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.—

⁸137. (New) The method of claim ⁴131, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

⁹138. (New) The method of claim ⁴131, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

¹⁰139. (New) The method of claim ⁴131, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

¹¹140. (New) The method of claim ⁵132, wherein the antibody further comprises a VL CDR 1 having an amino acid sequence of SEQ ID NO:39.

¹²141. (New) The method of claim ⁵132, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

¹³142. (New) The method of claim ⁵132, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

¹⁴143. (New) The method of claim ⁶133, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

¹⁵144. (New) The method of claim ⁶133, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

¹⁶145. (New) The method of claim ⁶133, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

17
146. (New) The method of claim 131, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

18
147. (New) The method of claim 131, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

19
148. (New) The method of claim 132, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

20
149. (New) The method of claim 146, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

21
150. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

22
151. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

23
152. (New) The method of claim 146, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

24
153. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

25
154. (New) The method of claim 147, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

26
155. (New) The method of claim 147, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

27
156. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

28
157. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

29
158. (New) The method of claim 148, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

30
159. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

³¹
160. (New) The method of claim ²⁰149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

³²
161. (New) The method of claim ²⁰149, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

³³
162. (New) The method of claim ⁷134, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

³⁴
--Claim ⁷163. The method of claim ⁷124, wherein the antibody further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.--

³⁵
165. (New) The method of claim ³³162, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

³⁶
166. (New) The method of claim ³³162, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

³⁷
167. (New) The method of claim ³³162, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

³⁸
168. (New) The method of claim ³³162, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

³⁹
169. (New) The method of claim ³⁴163, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

⁴⁰
170. (New) The method of claim ³⁴163, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

⁴¹
171. (New) The method of claim ³⁴163, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

42
--Claim 172. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR1 having an amino acid sequence of SEQ ID NO: 10, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

43
Claim 173. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR2 having an amino acid sequence of SEQ ID NO: 19, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

44
Claim 174. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 20, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.--

⁴⁵
175. (New) The method of claim ³⁵165, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

⁴⁶
176. (New) The method of claim ³⁵165, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

⁴⁷
177. (New) The method of claim ³⁵165, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

⁴⁸
178. (New) The method of claim ¹⁷146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

⁴⁹
179. (New) The method of claim ¹⁷146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

⁵⁰
180. (New) The method of claim ¹⁷146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

⁵¹
181. (New) The method of claim ¹⁷146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

⁵²
182. (New) The method of claim ¹⁸147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

⁵³
183. (New) The method of claim ¹⁸147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

⁵⁴
184. (New) The method of claim ¹⁸147, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

55

18

185. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

56

14

186. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

57

14

187. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

58

14

188. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

59

14

189. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

60

20

190. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

61

20

191. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

62

20

192. (New) The method of claim 149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

63

20

193. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

⁶⁴
194. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134, wherein the effective amount is 15 mg/kg or less, 10 mg/kg or less, 5 mg/kg or less or 3 mg/kg or less or 1.5 mg/kg or less.

⁶⁵
195. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134, wherein the effective neutralizing titer is at least 1 $\mu\text{g/ml}$, at least 2 $\mu\text{g/ml}$, at least 4 $\mu\text{g/ml}$, at least 6 $\mu\text{g/ml}$, at least 30 $\mu\text{g/ml}$, 35 $\mu\text{g/ml}$, at least 40 $\mu\text{g/ml}$, at least 50 $\mu\text{g/ml}$, at least 75 $\mu\text{g/ml}$, at least 100 $\mu\text{g/ml}$, at least 150 $\mu\text{g/ml}$ or at least 200 $\mu\text{g/ml}$.

⁶⁶
196. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134, wherein the effective neutralizing titer is maintained for at least 20 days, at least 25 days or at least 30 days after administration of the dose.

⁶⁷
197. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134, wherein the antibody is administered by a nebulizer or inhaler.

⁶⁸
198. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134, wherein the antibody is administered intramuscularly, intravenously or subcutaneously.

⁶⁹
199. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134, wherein the antibody is a monoclonal antibody, a human antibody, a humanized antibody, a multispecific antibody, a chimeric antibody, a Fab fragment, a single-chain Fv or a single chain antibody.

⁷⁰
200. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134, wherein the antibody is administered 1, 2, 3, 4 or 5 times during the RSV season.

⁷¹
201. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134, wherein the mammal is a human subject.

⁷²
202. (New) The method of claim ⁷¹201, wherein the human subject is a human infant, a human infant born prematurely or at risk of hospitalization for a RSV infection, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

⁷³
203. (New) The method of any one of claims ^{1 2 3 4-7}128, 129, 130 or 131-134 further comprising administering to the mammal hormonal therapy, immunotherapy or an anti-inflammatory agent.